PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12691780-5	2003	Chronic anxiolytic treatment with the selective CCK-B (CCK(2)) receptor antagonist, Ci-988 (0.3 mg/kg/day ip) or diazepam (2 mg/kg/day ip), induced numerous effects throughout the central nervous system (CNS), with Ci-988 inducing significant changes in the density of dopamine D(2) receptors, and diazepam producing marked changes in both dopamine D(2) and CCK-B receptor binding density as well as preproCCK mRNA expression.	Dopamine	269-277	cholecystokinin B receptor	Rattus norvegicus	55-71	
9871461-6	1998	Dopamine (DA) and cholecystokinin (CCK) selectively stimulate Asp release, via D1 and CCKB receptor subtypes, respectively.	Dopamine	0-8	cholecystokinin B receptor	Rattus norvegicus	75-99	
9871461-6	1998	Dopamine (DA) and cholecystokinin (CCK) selectively stimulate Asp release, via D1 and CCKB receptor subtypes, respectively.	Dopamine	10-12	cholecystokinin B receptor	Rattus norvegicus	75-99	
9272833-1	1997	Cholecystokinin (CCK) is co-localized with dopamine (DA) in the nucleus accumbens (NAC) where evidence suggests that CCK(B) receptor-mediated mechanisms inhibit, while CCK(A) receptor-mediated mechanisms facilitate, DA function.	Dopamine	43-51	cholecystokinin B receptor	Rattus norvegicus	117-132	
9272833-1	1997	Cholecystokinin (CCK) is co-localized with dopamine (DA) in the nucleus accumbens (NAC) where evidence suggests that CCK(B) receptor-mediated mechanisms inhibit, while CCK(A) receptor-mediated mechanisms facilitate, DA function.	Dopamine	53-55	cholecystokinin B receptor	Rattus norvegicus	117-132